Humacyte Inc (HUMA)

$1.30 +0.01 (0.78%)
Market Cap 241.58M
Revenue (ttm) 0.00
Net Income (ttm) -148.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,084,300
Avg Vol 5,685,622
Day's Range N/A - N/A
Shares Out 187.27M
Stochastic %K 72%
Beta 1.90
Analysts Strong Sell
Price Target $7.86

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
Iightning
Iightning Dec. 5 at 12:20 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HUMA Contract: Dec 19 $1C Entry: 0.33 Exit: 0.55 Return: +70.45% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
bioman2024
bioman2024 Dec. 4 at 6:28 PM
$HUMA …question. Does the DOW have to have a contract to purchase symvess, or…can they buy a quantity in advance of a contract. Thoughts?
1 · Reply
crowbaby333
crowbaby333 Dec. 4 at 4:55 PM
$HUMA
1 · Reply
Scmin
Scmin Dec. 4 at 4:02 PM
$HUMA did Laura sell more than 2 units to the DoD? Trump has a Hugh show of force at Venezuela. If Laura missed the opportunity having am ample supple there the DoD is just a smoke and mirrors contract. The DoD should have bought enough to help any military soldier that needs it. No news from Laura. Knock knock Laura The enemy knows we are there and a big buildup of your product would be a show of force...... OK Laura you dont get it, go bake cookies for Dougan or look for another house to buy.
3 · Reply
Michael_Krombopulos
Michael_Krombopulos Dec. 4 at 3:47 PM
$HUMA
0 · Reply
gtzmoney
gtzmoney Dec. 4 at 1:02 PM
$HUMA January 2025 Do you know what this price was ?
0 · Reply
Iightning
Iightning Dec. 4 at 7:59 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HUMA Contract: Dec 19 $0.5C Entry: 0.90 Exit: 1.59 Return: +77.16% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
bioman2024
bioman2024 Dec. 4 at 12:41 AM
$HUMA …off the wall ideas • Diabetic foot bypass: 80–90 % limb salvage • Vet racehorse/dog repairs: $80 M cash line • Pediatric Fontan conduits: growing grafts • Lymphedema bridges: stage-3 cure • DCD organ extensions: +35 % transplants
0 · Reply
Scmin
Scmin Dec. 3 at 10:32 PM
$HUMA Laura did great pumping up the stock so her hubby could sell at a great price! When it was FDA approved she put a price on it only the rich could afford because insurance companies would not approve such an expensive product without more data that it saved money. An experienced CEO would have put a great entry price on it so every doctor could have tried it. Insurance companies would have approved the price and there would have been thousands used already gathering positive data so when they raised the price surgeons would have demanded it and got it approved. Insurance would have seen the saving because of less or zero complications "infections" etc from its use. So its been approved almost a year now and we dont have 100 units sold. Thank you Laura for being soooo greedy and making a multi billion dollar company into a penny stock company. Greed and no experience as a CEO will do it. When are you filing for bankruptcy Laura? Dilute until there is no value at all.
2 · Reply
gtzmoney
gtzmoney Dec. 3 at 9:33 PM
$HUMA give us a run to $4.45 and I'll sell my 18k shares. I'll run 🏃
1 · Reply
Latest News on HUMA
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 20, 2025, 8:00 AM EST - 14 days ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 13, 2025, 8:00 AM EST - 21 days ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:21 PM EST - 22 days ago

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 22 days ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 10, 2025, 8:00 AM EST - 24 days ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 7, 2025, 9:00 AM EDT - 2 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 29, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 18, 2025, 7:00 AM EDT - 2 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 15, 2025, 7:00 AM EDT - 2 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Aug 12, 2025, 1:20 PM EDT - 4 months ago

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 10:00 AM EDT - 4 months ago

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 4 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jul 8, 2025, 8:00 AM EDT - 5 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Humacyte: Revenue Ramp From Symvess Incoming

Jun 11, 2025, 9:05 AM EDT - 6 months ago

Humacyte: Revenue Ramp From Symvess Incoming

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 9, 2025, 8:00 AM EDT - 6 months ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025, 4:05 PM EDT - 7 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:29 PM EDT - 7 months ago

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 7 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 7 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 1:48 PM EDT - 8 months ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 8 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 9 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 8:35 PM EDT - 9 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 9 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 9 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 9 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Mar 3, 2025, 8:00 AM EST - 9 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 10 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 27, 2025, 8:00 AM EST - 10 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 26, 2025, 8:00 AM EST - 10 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 10 months ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 11 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 11 months ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Iightning
Iightning Dec. 5 at 12:20 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HUMA Contract: Dec 19 $1C Entry: 0.33 Exit: 0.55 Return: +70.45% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
bioman2024
bioman2024 Dec. 4 at 6:28 PM
$HUMA …question. Does the DOW have to have a contract to purchase symvess, or…can they buy a quantity in advance of a contract. Thoughts?
1 · Reply
crowbaby333
crowbaby333 Dec. 4 at 4:55 PM
$HUMA
1 · Reply
Scmin
Scmin Dec. 4 at 4:02 PM
$HUMA did Laura sell more than 2 units to the DoD? Trump has a Hugh show of force at Venezuela. If Laura missed the opportunity having am ample supple there the DoD is just a smoke and mirrors contract. The DoD should have bought enough to help any military soldier that needs it. No news from Laura. Knock knock Laura The enemy knows we are there and a big buildup of your product would be a show of force...... OK Laura you dont get it, go bake cookies for Dougan or look for another house to buy.
3 · Reply
Michael_Krombopulos
Michael_Krombopulos Dec. 4 at 3:47 PM
$HUMA
0 · Reply
gtzmoney
gtzmoney Dec. 4 at 1:02 PM
$HUMA January 2025 Do you know what this price was ?
0 · Reply
Iightning
Iightning Dec. 4 at 7:59 AM
1ightning® Premium Options Alert (Actionable) Ticker: $HUMA Contract: Dec 19 $0.5C Entry: 0.90 Exit: 1.59 Return: +77.16% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
bioman2024
bioman2024 Dec. 4 at 12:41 AM
$HUMA …off the wall ideas • Diabetic foot bypass: 80–90 % limb salvage • Vet racehorse/dog repairs: $80 M cash line • Pediatric Fontan conduits: growing grafts • Lymphedema bridges: stage-3 cure • DCD organ extensions: +35 % transplants
0 · Reply
Scmin
Scmin Dec. 3 at 10:32 PM
$HUMA Laura did great pumping up the stock so her hubby could sell at a great price! When it was FDA approved she put a price on it only the rich could afford because insurance companies would not approve such an expensive product without more data that it saved money. An experienced CEO would have put a great entry price on it so every doctor could have tried it. Insurance companies would have approved the price and there would have been thousands used already gathering positive data so when they raised the price surgeons would have demanded it and got it approved. Insurance would have seen the saving because of less or zero complications "infections" etc from its use. So its been approved almost a year now and we dont have 100 units sold. Thank you Laura for being soooo greedy and making a multi billion dollar company into a penny stock company. Greed and no experience as a CEO will do it. When are you filing for bankruptcy Laura? Dilute until there is no value at all.
2 · Reply
gtzmoney
gtzmoney Dec. 3 at 9:33 PM
$HUMA give us a run to $4.45 and I'll sell my 18k shares. I'll run 🏃
1 · Reply
APman
APman Dec. 3 at 6:03 PM
$HUMA Move! Dammit! https://www.youtube.com/watch?v=xWL0DfKy5NU&t=128s
0 · Reply
moneyisfunduhr
moneyisfunduhr Dec. 3 at 5:50 PM
$HUMA so... what's the plan here? Wait it out? after Laura destroyed shareholder's value by more than 70% jeez I am not deeply in the red here but my gad Laura is just so terrible on how to run a public company at all
2 · Reply
Pitchie
Pitchie Dec. 3 at 10:57 AM
$HUMA https://finance.yahoo.com/news/humacyte-inc-nasdaq-huma-largest-102953642.html
2 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 3 at 12:35 AM
$HUMA Sticker Shock? did Jeffries say, "Terminate or WE will?"
3 · Reply
Ppbrain
Ppbrain Dec. 2 at 9:00 PM
$HUMA when will this garbage get back to $5
2 · Reply
steven1x
steven1x Dec. 2 at 7:17 PM
$HUMA how much was left?
2 · Reply
Scmin
Scmin Dec. 2 at 4:38 PM
$HUMA just a bunch of pumpers on this board. When does Laura drop the other shoe where we really are getting financing? The market is green and of course we are red. We lost more major holders in the last two weeks. Where is Laura? Oh yes, she is taking classes on how to be a CEO.
1 · Reply
moneyisfunduhr
moneyisfunduhr Dec. 2 at 4:23 PM
$HUMA goes down with negative market action, and plays dead while the market rips higher. Gad damn this stock is so frustrating lol
1 · Reply
MarketPro
MarketPro Dec. 2 at 3:45 PM
$HUMA Take your pick... FMC or other buyer in the wings. Mgt. knows the DOW order is coming in and is big. Mgt. is seeing a improved ramp. (Above expectations.) Choose one or more to win!
1 · Reply
TheYoungGeologist
TheYoungGeologist Dec. 2 at 2:05 PM
$HUMA adding $3,000 more at open because of the ATM cancellation
1 · Reply
Iightning
Iightning Dec. 2 at 2:29 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $HUMA **Contract:** Dec 19 $1C **Entry:** 0.30 **Exit:** 0.50 **Return:** **+68.00% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
datdude123
datdude123 Dec. 2 at 1:09 AM
$GALT $HUMA Another Shkreli short where he’s calling bunk data just like he did us and look at us now. This stock is very intriguing and reminding me of the gem we own. Data is revolutionary and already has FDA approval. Thoughts?
1 · Reply